CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients

• Status: Unknown status
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the relationship between cytochrome P450 (CYP) 2C19 genetic polymorphism and the steady-state blood concentration of voriconazole in Chinese patients with invasive pulmonary aspergillosis (IPA), and to assess the effects of voriconazole trough concentration on the prognosis of IPA patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: dingshifang
• Collaborators: Jinan Central Hospital; Jinan Military General Hospital; Qianfoshan Hospital; Shandong Provincial Hospital; Shandong thorax hospital
• Treatments: Voriconazole

Criteria

Inclusion Criteria:

• Proven, probable, or possible invasive pulmonary aspergillosis (IPA)

• Acute IPA defined as duration of clinical syndrome of <30 days.

• Treatment with voriconazole

• At least 18 years and older

• Weight >40 kg and ≤120 kg

• Given the informed consent

Exclusion Criteria:

• Patients allergic to azole(s)

• Patients who heve been prescribed voriconazole before

• Positive urine pregnancy test (if female)

• Patients with aspergilloma or chronic aspergillosis ( >1 month duration )

• Anticipated survival of less than 5 days or Karnofsky score <=20